July 2026– date –
-
TIDES USA 2026: Oligonucleotide CMC Innovations Address Manufacturing and Analytical Bottlenecks
Informa Connect USA Overview The TIDES USA 2026 summit focused on oligonucleotide CMC (Chemistry, Manufacturing, and Controls) innovations, discussing crucial process, analytical, and CMC strategies for clinical and commercial success. K... -
Eli Lilly’s Triple G-Agonist Retatrutide Succeeds in Two More Phase III Trials for Obesity and Type 2 Diabetes
GlobalData USA Overview Eli Lilly's GLP-1/GIP/Glucagon (GCG) triple receptor agonist, retatrutide, met primary endpoints in two additional Phase III trials (TRIUMPH-2 and TRIUMPH-3) for type 2 diabetes and obesity patients with establish... -
Blood-Brain Barrier Drug Delivery Summit (B3DD) Convenes to Overcome CNS Therapeutic Hurdles
News-Medical.net USA Overview The Blood-Brain Barrier Drug Delivery Summit (B3DD) addressed critical challenges in CNS drug delivery, focusing on bypassing the brain's selective permeability. Advanced DDS research into nanoparticles, lip... -
FDA Approves Sanofi’s Subcutaneous Isatuximab (Sarclisa Escena) for Multiple Myeloma, Enhancing Patient Convenience
Drugs.com USA Overview The U.S. FDA has approved Sanofi's subcutaneous formulation, Sarclisa Escena (isatuximab-irfc), for multiple myeloma, significantly improving administration convenience for patients. This new formulation reduces tr... -
FDA Approves Celcuity’s Breakthrough Gedatolisib for Advanced Breast Cancer with Priority Review Designation
Life Science Daily News USA Overview The FDA approved Celcuity's first-in-class PI3K/AKT/mTOR pathway inhibitor, gedatolisib, for advanced breast cancer on its PDUFA date of July 17, 2026. This approval, following Priority Review and Bre... -
Boehringer Ingelheim Initiates Phase II Trial for BI 3034701, a Potential First-in-Class Triple Receptor Agonist for Obesity
Boehringer Ingelheim Germany Overview Boehringer Ingelheim has launched a Phase II clinical trial for BI 3034701, an investigational triple GLP-1/GIP/NPY2 receptor agonist targeting patients with obesity and overweight. This molecule rep... -
bioRxiv Preprint: TLS11a Aptamer-Functionalized LNP Platform for Hepatocyte-Preferential mRNA Delivery and CRISPR LDLR-KO Model Established
bioRxiv USA Overview A preprint published in bioRxiv details the design and validation of an aptamer-functionalized lipid nanoparticle (LNP) platform for hepatocyte-preferential genome editing delivery, demonstrated using a multilevel-va... -
Eli Lilly Acquires AtaiBeckley to Accelerate Phase III Development of BPL-003 for Treatment-Resistant Depression and Mental Health
Eli Lilly and Company USA Overview Eli Lilly announced the acquisition of AtaiBeckley to accelerate the development of therapies for treatment-resistant depression (TRD) and other mental health conditions. AtaiBeckley's lead candidate, B... -
How Gene Therapies Get to Patients Faster: Liv Hospital Explores FDA’s Expedited Pathways
Liv Hospital Turkey Overview Liv Hospital has published a comprehensive article clarifying the U.S. FDA's expedited approval pathways for gene therapies, focusing on Breakthrough Therapy Designation and Accelerated Approval. These crucia... -
FDA Seeks Input on Psychedelic Drug Therapeutic Use: Exploring Psilocybin and MDMA for Depression and PTSD
RAPS USA Overview The U.S. FDA is soliciting public input on the potential therapeutic uses of psychedelic drugs, specifically psilocybin for depression and MDMA-assisted therapy for PTSD. While the FDA granted Breakthrough Therapy Desig...
